Connection
Christina Aquilante to Sequence Analysis, DNA
This is a "connection" page, showing publications Christina Aquilante has written about Sequence Analysis, DNA.
|
|
Connection Strength |
|
 |
|
 |
|
0.276 |
|
|
|
-
Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy. 2004 Jun; 24(6):720-6.
Score: 0.189
-
Lin M, Aquilante C, Johnson JA, Wu R. Sequencing drug response with HapMap. Pharmacogenomics J. 2005; 5(3):149-56.
Score: 0.049
-
Beitelshees AL, Aquilante CL, Allayee H, Langaee TY, Welder GJ, Schofield RS, Zineh I. CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults. Hum Genomics. 2012 Aug 02; 6:9.
Score: 0.021
-
Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov; 64(5):1071-9.
Score: 0.017